Literature DB >> 371856

Treatment of hypertension with nifedipine, a calcium antagonistic agent.

M T Olivari, C Bartorelli, A Polese, C Fiorentini, P Moruzzi, M D Guazzi.   

Abstract

Hemodynamic monitoring after a single dose (10 mg) of nifedipine in 27 primary hypertensive subjects (diastolic pressure greater than 110 mm Hg) documented that this calcium antagonistic agent exerts a potent arteriolar vasodilating action, which results in prompt (-21% of control at 30 minutes) and persistent (-16% of control at 120 minutes) fall in mean arterial pressure associated with a rise in cardiac output and pulse rate. The same patients received oral treatment for 3 weeks. Hourly pressure readings showed that 1) the antihypertensive response to each dose lasts 8--12 hours; and 2) nifedipine every 6 hours significantly reduced blood pressure throughout the 24 hours, without postural hypotension. Side effect were short-lasting (headache in five patients, palpitation without arrhythmias in eight patients, burning sensation in the face and legs in five patients and sporadic extrasystoles in five patients) and tended to disappear with continued treatment. Development of drug resistance, sodium retention, plasma volume expansion, renin release or angina pectoris were not observed during the study. Although these findings seem to differentiate nifedipine from other vasodilators currently used in the treatment of hypertension, broader experience and more prolonged trials with nifedipine as an antihypertensive agent will be needed before conclusions can be drawn on these particular aspects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371856     DOI: 10.1161/01.cir.59.5.1056

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  64 in total

1.  Pressure induces intracellular calcium changes in juxtaglomerular cells in perfused afferent arterioles.

Authors:  En Yin Lai; Yibing Wang; Anders Erik Gosta Persson; Roy Davis Manning; Ruisheng Liu
Journal:  Hypertens Res       Date:  2011-06-02       Impact factor: 3.872

2.  Long-term therapy with slow-release nifedipine in essential hypertension.

Authors:  F Arrigo; F Consolo
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Use of nifedipine in hypertension and Raynaud's phenomenon.

Authors:  W Kiowski; P Erne; F R Bühler
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 4.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

5.  Nicardipine hydrochloride in essential hypertension--a controlled study.

Authors:  J Asplund
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

6.  Renal effects of manidipine hydrochloride. A new calcium antagonist in hypertensive patients.

Authors:  T Takabatake; H Ohta; T Sasaki; S Satoh; K Ohta; T Ise; K Kobayashi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients.

Authors:  J R M'Buyamba-Kabangu; B Lepira; R Fagard; P Lijnen; M Ditu; K A Tshiani; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine.

Authors:  H E Sluiter; F T Huysmans; T A Thien; R A Koene
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.

Authors:  F P Cappuccio; N D Markandu; F A Tucker; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Short-term effects of felodipine, a new dihydropyridine, in hypertension.

Authors:  O Andersson; C Bengtsson; D Elmfeldt; K Haglund; T Hedner; P Seideman; K H Sjöberg; E Strömgren; H Aberg; J Ostman
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.